This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


New approach against fatty liver: Molecular pathway identified

New approach against fatty liver
Scanning electron micrograph of a small blood vessel in the liver, which contains many windows (small, dark grey dots). Credit: HHU / Sydney Balkenhol

Fatty liver disease (SLD) is increasingly causing failure of the liver as a vital organ. A team led by researchers from the Institute of Metabolic Physiology at Heinrich Heine University Düsseldorf (HHU) in collaboration with the German Diabetes Center (DDZ) and other partners has now discovered that a saturated fatty acid in blood vessels leads to the production of the signaling molecule SEMA3A, which closes the "windows" in the blood vessels. This hinders the transport of fat from the liver to the adipose tissue.

In the journal Nature Cardiovascular Research, the researchers report that the windows open again and the fat in the liver is reduced when SEMA3A is inhibited.

In particular, metabolic dysfunction-associated SLD (MASLD) can develop due to adverse lifestyle factors such as a high-energy diet and little exercise. It already affects around a third of all people worldwide.

Initially, MASLD has no pathological effects, but it can develop into inflammation of the liver. In the long term, this may lead to liver cirrhosis, liver failure or even liver cancer. There is no substitute procedure that can take over the function of the liver in the long term, such as dialysis for kidney failure.

Those affected are at high risk and may only be cured by a liver transplant. In addition, people with MASLD have an increased risk of developing type 2 diabetes mellitus or dying from cardiovascular diseases. Obesity favors MASLD, but not all obese people are affected. And conversely, slim people can also develop the disease.

The molecular causes of the development of MASLD are not fully understood. A team of researchers from HHU, the DDZ (Leibniz Center for Diabetes Research at HHU), Düsseldorf University Hospital (UKD) and Forschungszentrum Jülich (FZJ) have now discovered an important aspect that explains how MASLD develops.

The leading role is played by windows (Latin: fenestrae) in the endothelial cells of blood vessels, through which substances are exchanged between and blood. The liver uses these tiny windows to release excess fat particles into the adipose tissue via the bloodstream.

The researchers discovered that these windows are closed by a mechanism in which the signaling molecule SEMA3A (semaphorin-3A) plays the central part. This molecule is produced in blood vessels when they are overly exposed to the saturated fatty acid "palmitic acid."

Sydney Balkenhol from the Institute of Metabolic Physiology at HHU and the DDZ, first author of the study, points to a discovery made by the team using scanning : The "windows" in the smallest blood vessels of the liver were also closed in mice with fatty liver and type 2 .

Dr. Daniel Eberhard, the other first author, adds, "We were also able to reverse the effect. By inhibiting the signaling molecule, we could defat the liver and thus improve its function again."

Corresponding author Dr. Eckhard Lammert, professor and head of the Institute of Metabolic Physiology at HHU and the Institute of Vascular and Islet Cell Biology at the DDZ, hopes that the discoveries will also lead to a therapeutic approach for humans in the long term.

"It may be possible to use the SEMA3A signaling molecule we identified to prevent MASLD and its consequences at an early stage. However, we first need to investigate the processes in humans in detail."

More information: Daniel Eberhard et al, Semaphorin-3A regulates liver sinusoidal endothelial cell porosity and promotes hepatic steatosis, Nature Cardiovascular Research (2024). DOI: 10.1038/s44161-024-00487-z

Citation: New approach against fatty liver: Molecular pathway identified (2024, June 14) retrieved 14 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Targeting bile acid pathways offers hope for liver disease treatment


Feedback to editors